Introduction

The Royal College of Nursing (RCN) was invited to review the Appraisal Consultation Document (ACD) for Botulinum toxin type A for the prophylaxis of headaches associated with chronic migraine.

Nurses caring for people with this condition were invited to review this document on behalf of the RCN.

Appraisal Consultation Document – RCN Response

The Royal College of Nursing welcomes the opportunity to review this document. The RCN’s response to the four questions on which comments were requested is set out below:

i) **Has the relevant evidence has been taken into account?**

The evidence considered seems comprehensive.

ii) **Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?**

We would ask that the summaries of the clinical and cost effectiveness of this appraisal be aligned to the clinical pathway followed by patients with headaches associated with chronic migraine. The preliminary views
on resource impact and implications should be in line with established standard clinical practice.

iii) Are the provisional recommendations sound and a suitable basis for guidance to the NHS?

The RCN notes that Appraisal Committee has recommended that NICE requests further information on the clinical and cost effectiveness of botulinum toxin type A from the manufacturer, as described in 1.3 to 1.5 of the ACD. We also note that the recommendation that this information should be made available for the next Appraisal Committee meeting.

The RCN looks forward to receiving the Committee’s view following consideration of this information.

iv) Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of gender, race, disability, age, sexual orientation, religion or belief?

None that we are aware of at this stage.

v) Are there any equality-related issues that need special consideration that are not covered in the appraisal consultation document?

We are not aware of any specific issue at this stage. We would however, ask that any guidance issued should show that an analysis of equality impact has been considered and that the guidance demonstrates an understanding of issues relating to all the protected characteristics where appropriate.